Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Industry

News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

AI and glaucoma: "With our technique, you’d be able to quantify the earliest change"

Researchers have combined OCT technology, adaptive optics and deep neural networks to aid the detection of neurodegenerative disease

handshake
Pixabay/kiquebg

Scientists at Duke University in the US have utilised optical coherence tomography (OCT), adaptive optics and deep neural networks to assist the detection and management of neurodegenerative conditions such as glaucoma.

The research, which was published in Optica, involved developing a deep learning algorithm that can identify and trace the shapes of ganglion cells from adaptive optics OCT scans.

Testing the algorithm on both scans from healthy and glaucomatous eyes, the framework was able to accurately segment ganglion cells from both samples and also differentiate whether scans were from healthy patients or those with glaucoma.

Post doctoral researcher at Duke University, Somayyeh Soltanian-Zadeh, explained that the technology performed better than human experts in the task.

“It’s superior to other state-of-the-art networks that can process volumetric biomedical images,” she said.

Professor of Biomedical Engineering at Duke University, Sina Farsiu, highlighted that the technology could potentially shorten clinical trials because clinicians would be able to see and measure initial effects of treatment.

“With our technique, you'd be able to quantify the earliest change,” he said.